Joel Greenblatt Vir Biotechnology, Inc. Transaction History

Gotham Asset Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$7.63 - $12.66 $77,429 - $128,473	10,148 New	10,148 $90,000
Q1 2023 May 15, 2023	SELL	$22.26 - $30.85 $517,700 - $717,478	-23,257 Reduced 48.75%	24,453 $569,000
Q4 2022 Feb 14, 2023	SELL	$19.96 - $28.22 $488,501 - $690,656	-24,474 Reduced 33.91%	47,710 $1.21 Million
Q3 2022 Nov 14, 2022	BUY	$18.26 - $31.1 $22,295 - $37,973	1,221 Added 1.72%	72,184 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $1.35 Million - $1.89 Million	70,963 New	70,963 $1.81 Million
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $212,217 - $400,700	-10,015 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $95,635 - $166,844	3,088 Added 44.58%	10,015 $419,000
Q3 2021 Nov 15, 2021	BUY	$34.9 - $54.54 $241,752 - $377,798	6,927 New	6,927 $301,000

218

87M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $982M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.